Epimmune Licenses Gene Delivery Technologies

Epimmune Inc. has licensed Valentis, Inc.’s proprietary PINC gene delivery technology for Epimmune’s preventive and therapeutic DNA vaccines in development against the human immunodeficiency virus (HIV) and the hepatitis C virus (HCV). Valentis has granted Epimmune a non-exclusive license to certain patented and non-patented technology for use in developing DNA vaccines against HIV and HCV Read more about Epimmune Licenses Gene Delivery Technologies[…]

Valentis Licenses Geneswitch Technology To Wyeth-Ayers

Valentis, Inc. has granted a non-exclusive license of the Company’s GeneSwitch gene regulation technology to Wyeth-Ayerst Laboratories. The GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, aiding in the identification and characterization of a gene’s function. Valentis is currently developing the GeneSwitch system as Read more about Valentis Licenses Geneswitch Technology To Wyeth-Ayers[…]

heska corporation

Heska Licenses Valentis Gene Delivery Technology

Heska Corporation has licensed gene delivery and DNA manufacturing technology from Valentis, Inc. The technology will be used by Heska to complete development of a novel gene medicine for the treatment of canine cancer. Specific terms of the agreement, which include an up-front license fee, milestone payments and a royalty, were not disclosed. Dr. Dan Read more about Heska Licenses Valentis Gene Delivery Technology[…]